Development of diagnostic imaging and radioimmunotherapy targeting metastasis-associated factor

2016 Fiscal Year Final Research Report

• Project/Area Number: 25861140
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Radiation science
• Research Institution: National Institutes for Quantum and Radiological Science and Technology
• Principal Investigator: Sugyo Aya 国立研究開発法人量子科学技術研究開発機構, 放射線医学総合研究所 分子イメージング診断治療研究部, 技術員(任常) (00415415)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: 内照射治療 / EMMPRIN

Outline of Final Research Achievements

An antibody Hs8001 recognizing a metastasis-associated factor was labeled with In-111 and the biodistribution in mice bearing BxPC-3 tumor showed high tumor uptake and low uptake in normal organs. Hs8001 labeled with a positron emitter Zr-89 clearly visualized tumors. The therapeutic efficacy of 90Y-labeled Hs8001 suppressed tumor growth of BxPC-3, whereas the tumor size did not decrease. Next, combination therapy of 90Y-labeled antibody with an anti-cancer drug gemcitabine reduced tumor size. These results suggest that the combination therapy of 90Y-labeled antibody with gemcitabine is a promising therapy for pancreatic cancer. In the present study, we successfully developed a new diagnostic imaging method and a combination therapeutic protocol with 90Y-labeled Hs8001 and gemcitabine.

Free Research Field

核医学